Upgrade to SI Premium - Free Trial

Teva Pharma (TEVA) PT Raised to $42 at UBS

April 30, 2026 6:25 AM
UBS analyst Ashwani Verma raised the price target on Teva Pharma (NYSE: TEVA) to $42.00 (from $36.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change